ArticleCell death & disease2018
Insulin-like growth factor 2 is a key mitogen driving liver repopulation in mice.
Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Epitranscriptomic regulation of diabetic EndMT in HAECs: METTL3-dependent mFunctional & integrative genomics · 2026Article
- Generation of proliferative hESC-derived grape-clustered hepatocyte organoids with multipolar architecture as regenerative counterpart via synergy of YAP and IGF2 pathways.Cell death & disease · 2026Article
- H19 and IGF2 imprinting from embryogenesis to oncogenesis.Frontiers in cell and developmental biology · 2026Review
- From renal development to pathology: An analysis of the multilevel role of insulin‑like growth factor 2 (Review).Molecular medicine reports · 2026Review
- Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering.Journal of hepatology · 2025Article
- Role of mitogens in normal and pathological liver regeneration.Hepatology communications · 2025Review
- A p21-ATD mouse model for monitoring and eliminating senescent cells and its application in liver regeneration post injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Liver cell therapies: cellular sources and grafting strategies.Frontiers of medicine · 2023Review
- Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Review
- Genetics, epigenetics and transgenerational transmission of obesity in children.Frontiers in endocrinology · 2022Review
- Vesiculin derived from IGF-II drives increased islet cell mass in a mouse model of pre-diabetes.Islets · 2022Article
- Mouse Models of Liver Parenchyma Injuries and Regeneration.Frontiers in cell and developmental biology · 2022Review
- Paternal Exercise Improves the Metabolic Health of Offspring via Epigenetic Modulation of the Germline.International journal of molecular sciences · 2021Article
- Hepatocyte organoids and cell transplantation: What the future holds.Experimental & molecular medicine · 2021Review
- Aged-related Function Disorder of Liver is Reversed after Exposing to Young MilieuAging and disease · 2021Article
- Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells.Oncotarget · 2020Article
- IFN-I Independent Antiviral Immune Response to Vesicular Stomatitis Virus Challenge in Mouse Brain.Vaccines · 2020Article
- Hormonal Contribution to Liver Regeneration.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Review
- Autophagy suppression of trophoblast cells induces pregnancy loss by activating decidual NK cytotoxicity and inhibiting trophoblast invasion.Cell communication and signaling : CCS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
Hepatocyte transplantation holds great promise as an alternative to orthotopic organ transplantation in the treatment of liver diseases. However, obtaining clinically meaningful levels of liver repopulation has not been achieved because the mechanisms regulating hepatocyte proliferation in recipient livers have not yet been well characterized. In the mouse model of Hereditary Tyrosinemia Type I, the fumarylacetoacetate hydrolase-deficient (Fah
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.